Merck & Co. Gardasil Sales Lawsuit
Analysis based on 7 articles · First reported Mar 15, 2025 · Last updated Apr 10, 2025
The market is impacted by the federal securities class action lawsuit against Merck & Co., which caused its stock price to fall by 9.1%. This event highlights the risks associated with companies making overly optimistic forecasts, especially in key international markets like China.
Faruqi & Faruqi is investigating Merck & Co. for allegedly violating federal securities laws by making false and misleading statements about the expected revenue from Gardasil sales, particularly its growth in China. The complaint alleges that Merck & Co. lacked visibility into demand in China, leading to inflated inventory for its distributor, Jiang Rensheng. On February 4, 2025, Merck & Co. announced a 3% decline in Gardasil sales to $8.6 billion and a temporary pause in shipments to China, causing its stock price to drop by $9.05 per share, or 9.1%. Investors who suffered losses exceeding $100,000 between February 3, 2022, and February 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the April 14, 2025, deadline to seek the role of lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard